EHDN-Endorsed Study: AMT-130 (uniQure)
On 29 Sept, uniQure announced additional data from its ongoing phase 1/2 studies, comparing updated 36-month and 48-month outcomes with propensity score-matched external controls: uniqure.gcs-web.com/news-release...